Thus, it was demonstrated that IBC was also a heterogeneous disease with variant molecular subtypes associated with distinct prognostic outcomes as other common breast cancers, and systemic therapies such as endocrinotherapy and anti-HER2 targeted therapy were effective for the treatment of IBC. The gene discussed is ERBB2; the disease is inflammatory breast carcinoma.